BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 37004094)

  • 1. Treatment with decitabine induces the expression of stemness markers, PD-L1 and NY-ESO-1 in colorectal cancer: potential for combined chemoimmunotherapy.
    Taib N; Merhi M; Inchakalody V; Mestiri S; Hydrose S; Makni-Maalej K; Raza A; Sahir F; Azizi F; Nizamuddin PB; Fernandes Q; Yoosuf ZSKM; Almoghrabi S; Al-Zaidan L; Shablak A; Uddin S; Maccalli C; Al Homsi MU; Dermime S
    J Transl Med; 2023 Mar; 21(1):235. PubMed ID: 37004094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigenetic modulation to enable antigen-specific T-cell therapy of colorectal cancer.
    Chou J; Voong LN; Mortales CL; Towlerton AM; Pollack SM; Chen X; Yee C; Robbins PF; Warren EH
    J Immunother; 2012; 35(2):131-41. PubMed ID: 22306901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A potential role for immunotherapy in thyroid cancer by enhancing NY-ESO-1 cancer antigen expression.
    Gunda V; Frederick DT; Bernasconi MJ; Wargo JA; Parangi S
    Thyroid; 2014 Aug; 24(8):1241-50. PubMed ID: 24811699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The molecular mechanisms of apoptosis accompanied with the epigenetic regulation of the NY-ESO-1 antigen in non-small lung cancer cells treated with decitabine (5-aza-CdR).
    Inchakalody VP; Hydrose SP; Krishnankutty R; Merhi M; Therachiyil L; Sasidharan Nair V; Elashi AA; Khan AQ; Taleb S; Raza A; Yoosuf ZSKM; Fernandes Q; Al-Zaidan L; Mestiri S; Taib N; Bedhiafi T; Moustafa D; Assami L; Maalej KM; Elkord E; Uddin S; Al Homsi U; Dermime S
    Eur J Pharmacol; 2023 Apr; 945():175612. PubMed ID: 36822455
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment with 5-Aza-2'-Deoxycytidine Induces Expression of NY-ESO-1 and Facilitates Cytotoxic T Lymphocyte-Mediated Tumor Cell Killing.
    Klar AS; Gopinadh J; Kleber S; Wadle A; Renner C
    PLoS One; 2015; 10(10):e0139221. PubMed ID: 26447882
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decitabine enhances targeting of AML cells by NY-ESO-1-specific TCR-T cells and promotes the maintenance of effector function and the memory phenotype.
    Kang S; Wang L; Xu L; Wang R; Kang Q; Gao X; Yu L
    Oncogene; 2022 Oct; 41(42):4696-4708. PubMed ID: 36097193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sequential 5-Aza-2 deoxycytidine-depsipeptide FR901228 treatment induces apoptosis preferentially in cancer cells and facilitates their recognition by cytolytic T lymphocytes specific for NY-ESO-1.
    Weiser TS; Guo ZS; Ohnmacht GA; Parkhurst ML; Tong-On P; Marincola FM; Fischette MR; Yu X; Chen GA; Hong JA; Stewart JH; Nguyen DM; Rosenberg SA; Schrump DS
    J Immunother; 2001; 24(2):151-61. PubMed ID: 11265773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of new HDAC inhibitors for immunotherapy of malignant pleural mesothelioma.
    Bensaid D; Blondy T; Deshayes S; Dehame V; Bertrand P; Grégoire M; Errami M; Blanquart C
    Clin Epigenetics; 2018; 10():79. PubMed ID: 29946373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor LAG-3 and NY-ESO-1 expression predict durable clinical benefits of immune checkpoint inhibitors in advanced non-small cell lung cancer.
    Jung EH; Jang HR; Kim SH; Suh KJ; Kim YJ; Lee JH; Chung JH; Kim M; Keam B; Kim TM; Kim DW; Heo DS; Lee JS
    Thorac Cancer; 2021 Mar; 12(5):619-630. PubMed ID: 33458968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NY-ESO-1 Vaccination in Combination with Decitabine Induces Antigen-Specific T-lymphocyte Responses in Patients with Myelodysplastic Syndrome.
    Griffiths EA; Srivastava P; Matsuzaki J; Brumberger Z; Wang ES; Kocent J; Miller A; Roloff GW; Wong HY; Paluch BE; Lutgen-Dunckley LG; Martens BL; Odunsi K; Karpf AR; Hourigan CS; Nemeth MJ
    Clin Cancer Res; 2018 Mar; 24(5):1019-1029. PubMed ID: 28947565
    [No Abstract]   [Full Text] [Related]  

  • 11. The DNA demethylating agent 5-aza-2'-deoxycytidine induces expression of NY-ESO-1 and other cancer/testis antigens in myeloid leukemia cells.
    Almstedt M; Blagitko-Dorfs N; Duque-Afonso J; Karbach J; Pfeifer D; Jäger E; Lübbert M
    Leuk Res; 2010 Jul; 34(7):899-905. PubMed ID: 20381863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive and prognostic effect of CD133 and cancer-testis antigens in stage Ib-IIIA non-small cell lung cancer.
    Su C; Xu Y; Li X; Ren S; Zhao C; Hou L; Ye Z; Zhou C
    Int J Clin Exp Pathol; 2015; 8(5):5509-18. PubMed ID: 26191258
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decitabine enhances tumor recognition by T cells through upregulating the MAGE-A3 expression in esophageal carcinoma.
    Shi X; Chen X; Fang B; Ping Y; Qin G; Yue D; Li F; Yang S; Zhang Y
    Biomed Pharmacother; 2019 Apr; 112():108632. PubMed ID: 30797153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decitabine Augments Chemotherapy-Induced PD-L1 Upregulation for PD-L1 Blockade in Colorectal Cancer.
    Huang KC; Chiang SF; Chen WT; Chen TW; Hu CH; Yang PC; Ke TW; Chao KSC
    Cancers (Basel); 2020 Feb; 12(2):. PubMed ID: 32079180
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of a specific CD8+ T-cell response to cancer/testis antigens by demethylating pre-treatment against osteosarcoma.
    Li B; Zhu X; Sun L; Yuan L; Zhang J; Li H; Ye Z
    Oncotarget; 2014 Nov; 5(21):10791-802. PubMed ID: 25301731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epigenetic potentiation of NY-ESO-1 vaccine therapy in human ovarian cancer.
    Odunsi K; Matsuzaki J; James SR; Mhawech-Fauceglia P; Tsuji T; Miller A; Zhang W; Akers SN; Griffiths EA; Miliotto A; Beck A; Batt CA; Ritter G; Lele S; Gnjatic S; Karpf AR
    Cancer Immunol Res; 2014 Jan; 2(1):37-49. PubMed ID: 24535937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decitabine facilitates immune recognition of sarcoma cells by upregulating CT antigens, MHC molecules, and ICAM-1.
    Krishnadas DK; Bao L; Bai F; Chencheri SC; Lucas K
    Tumour Biol; 2014 Jun; 35(6):5753-62. PubMed ID: 24584817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression profile of cancer-testis genes in 121 human colorectal cancer tissue and adjacent normal tissue.
    Li M; Yuan YH; Han Y; Liu YX; Yan L; Wang Y; Gu J
    Clin Cancer Res; 2005 Mar; 11(5):1809-14. PubMed ID: 15756003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Promoter hypomethylation of NY-ESO-1, association with clinicopathological features and PD-L1 expression in non-small cell lung cancer.
    Chüeh AC; Liew MS; Russell PA; Walkiewicz M; Jayachandran A; Starmans MHW; Boutros PC; Wright G; Barnett SA; Mariadason JM; John T
    Oncotarget; 2017 Sep; 8(43):74036-74048. PubMed ID: 29088766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decitabine immunosensitizes human gliomas to NY-ESO-1 specific T lymphocyte targeting through the Fas/Fas ligand pathway.
    Konkankit VV; Kim W; Koya RC; Eskin A; Dam MA; Nelson S; Ribas A; Liau LM; Prins RM
    J Transl Med; 2011 Nov; 9():192. PubMed ID: 22060015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.